Journal
CLINICAL PEDIATRICS
Volume 55, Issue 10, Pages 957-974Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/0009922815617973
Keywords
infants; children; genetic subtype; Prader-Willi syndrome; standardized growth curves; growth hormone treatment
Categories
Funding
- Prader-Willi Syndrome Association (USA)
- Angelman, Rett and Prader-Willi Syndromes Consortium [U54 HD06122]
- National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN)
- NIH Office of Rare Disease Research (ORDR) at the National Center of Advancing Translational Science (NCATS)
- National Institute of Child Health and Human Development (NICHD)
Ask authors/readers for more resources
The purpose of the current study was to develop syndrome-specific standardized growth curves for growth hormone-treated Prader-Willi syndrome (PWS) individuals aged 0 to 18 years. Anthropometric growth-related measures were obtained on 171 subjects with PWS who were treated with growth hormone for at least 40% of their lifespan. They had no history of scoliosis. PWS standardized growth curves were developed for 7 percentile ranges using the LMS method for weight, height, head circumference, weight/length, and BMI along with normative 3rd, 50th, and 97th percentiles plotted using control data from the literature and growth databases. Percentiles were plotted on growth charts for comparison purposes. Growth hormone treatment appears to normalize stature and markedly improves weight in PWS compared with standardized curves for non-growth hormone-treated PWS individuals. Growth chart implications and recommended usage are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
